ReviewFrontiers in immunology2023
Integrated control strategies for dengue, Zika, and Chikungunya virus infections.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Beyond the Mosquito: Social Determinants of Health and Global Strategies for Aedes-Borne Disease Control.Tropical medicine & international health : TM & IH · 2026Pooled it
- Diagnostic accuracy of recombinase polymerase amplification-based assays for mosquito-borne virus detection in clinical samples: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2026Pooled it
- Identification of 4-Amino-7-chloroquinoline Derivative with In Vitro Activity Against Chikungunya Virus.Current microbiology · 2026Article
- Epidemiological and molecular analysis of the Chikungunya virus outbreak in the state of Rondônia.Infection · 2026Review
- Chikungunya virus: global epidemiology, transmission dynamics, and emerging challenges for public health.Infection · 2026Review
- Retinoic acid is a translation inhibitor against chikungunya virus both in vitro and invivo.Virologica Sinica · 2026Article
- Strategies forOne health (Amsterdam, Netherlands) · 2026Review
- The Second Silent Pandemic: Why Arboviruses Demand an Orchestrated Global Health Response.Pathogens (Basel, Switzerland) · 2026Review
- Chikungunya: global epidemiology, clinical spectrum, and vector control-lessons for China from the 2025 Guangdong outbreak.Archives of toxicology · 2026Review
- Clinical epidemiology and viral genomics insights from a Chikungunya fever outbreak in South China, 2025.Frontiers in cellular and infection microbiology · 2026Article
- The CRISPR-Cas toolkit for mosquito-borne virus surveillance: detection, tracing, and discovery.Frontiers in cellular and infection microbiology · 2026Review
- Bioactive Flavanone Glycoside Isolated from Leaves ofACS omega · 2025Article
- Understanding the social determinants of Aedes-borne diseases in Iran: A qualitative exploration of challenges and policy solutions.PLoS neglected tropical diseases · 2025Article
- Identification of Small Molecules as Zika Virus Entry Inhibitors.International journal of molecular sciences · 2025Article
- A novel ZIKV-targeted scRNA-seq method for precise quantification of ZIKV RNA.Journal of virology · 2025Article
- Codon Usage Evolution in Viruses: Implications for Survival and Pathogenicity.Journal of molecular evolution · 2025Review
- Bionomics of the primary arbovirus vectors Aedes aegypti and Aedes albopictus in southeastern Benin.Tropical medicine and health · 2025Article
- Arboviruses and COVID-19: Global Health Challenges and Human Enhancement Technologies.Bioengineering (Basel, Switzerland) · 2025Article
- A VLPs based vaccine protects against Zika virus infection and prevents cerebral and testicular damage.NPJ vaccines · 2025Article
- Leveraging machine learning on the role of hospitalizations in the dynamics of dengue spread in Brazil: an ecological study of health systems resilience.Lancet regional health. Americas · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arboviruses are a major threat to public health in tropical regions, encompassing over 534 distinct species, with 134 capable of causing diseases in humans. These viruses are transmitted through arthropod vectors that cause symptoms such as fever, headache, joint pains, and rash, in addition to more serious cases that can lead to death. Among the arboviruses, dengue virus stands out as the most prevalent, annually affecting approximately 16.2 million individuals solely in the Americas. Furthermore, the re-emergence of the Zika virus and the recurrent outbreaks of chikungunya in Africa, Asia, Europe, and the Americas, with one million cases reported annually, underscore the urgency of addressing this public health challenge. In this manuscript we discuss the epidemiology, viral structure, pathogenicity and integrated control strategies to combat arboviruses, and the most used tools, such as vaccines, monoclonal antibodies, treatment, etc., in addition to presenting future perspectives for the control of arboviruses. Currently, specific medications for treating arbovirus infections are lacking, and symptom management remains the primary approach. However, promising advancements have been made in certain treatments, such as Chloroquine, Niclosamide, and Isatin derivatives, which have demonstrated notable antiviral properties against these arboviruses
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.